1. Pink Sheet
  2. >>Market Access
  3. >>Pricing Debate

HHS Message On Value-Based Drug Pricing Complicated But Themes Emerging

 
• By Cathy Kelly

US government involvement in value assessments for prescription drugs and the benefits of outcomes-based contracting in lowering drug prices are among the issues being discussed.

Low value

Recent public comments by HHS officials on the Trump Administration’s agenda for lowering drug pricing shed some light on the department’s current thinking about value-based pricing for drugs.

Here’s what we’ve heard: HHS doesn’t like the idea of the US government defining the value of prescription drugs and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

Sticker Shock? Cost Of Orphan Drug Medicare Negotiation Relief May Complicate Future Fixes

 
• By Cathy Kelly

Heavy lobbying produced relief for orphan drugs in President Trump's budget reconciliation law and the cost of the changes to Medicare now is becoming clearer.

Colorado Board Adopts Medicare Maximum Fair Price For Enbrel, Assumes Amgen ‘Amenable’

 
• By Cathy Kelly

The state’s prescription drug affordability board could be the first to recommend an upper payment limit for a prescription drug.

Medicare Part D Plans Turn to Coinsurance, Higher Deductibles Amid IRA Changes

 
• By Tim Casey

Newly implemented IRA provisions may not necessarily lower drug costs for those enrolled in Medicare Part D plans, according to research by the USC Schaeffer Center for Health Policy and Economics.

Pharma’s Move Into Direct-To-Patient Sales Facing Legal, Practical and Political Hurdles

 
• By Cathy Kelly

Only a handful programs by pharmaceutical firms are in operation so far. Some companies may be waiting to see if a broad government-facilitated DTC initiative will materialize.

More from Market Access

Colorado Board Adopts Medicare Maximum Fair Price For Enbrel, Assumes Amgen ‘Amenable’

 
• By Cathy Kelly

The state’s prescription drug affordability board could be the first to recommend an upper payment limit for a prescription drug.

MSD Works To Reverse English Funding Refusal For Winrevair; Reimbursement Plans Progress Elsewhere

 
• By Neena Brizmohun

MSD is gearing up to demonstrate the value of its pulmonary arterial hypertension drug, after England’s health technology assessment institute provisionally said the product was not cost-effective. Meanwhile, the company told the Pink Sheet about Winrevair’s reimbursement status across Europe.

China NHSA Releases Preliminary Innovative Drug List For First Time

 
• By Xu Hu

China’s NHSA in August released for the first time a preliminary list of innovative drugs under commercial insurance, along with a preliminary list of products under the National Reimbursement Drug List.